系統識別號 U0026-2408201815105900
論文名稱(中文) 困難梭狀桿菌RT017與其他毒性菌株之表現型比較
論文名稱(英文) Phenotypic comparison of Clostridium dificile RT017 strains with other toxigenic strains
校院名稱 成功大學
系所名稱(中) 醫學檢驗生物技術學系
系所名稱(英) Department of Medical Laboratory Science and Biotechnology
學年度 106
學期 2
出版年 107
研究生(中文) 郭明渝
研究生(英文) Ming-Yu Guo
學號 T36051028
學位類別 碩士
語文別 英文
論文頁數 58頁
口試委員 指導教授-蔡佩珍
中文關鍵字 困難梭狀桿菌  核醣型017  自誘導物-2  秀麗隱桿線蟲 
英文關鍵字 Clostridium. difficile  Ribotype 017  Autoinducer-2  Caenorhabditis. elegans 
中文摘要 困難梭狀桿菌為全世界新興的院內感染之重要病原,引起的臨床症狀特別是在長期使用廣效性抗生素的患者引發嚴重的腹瀉和偽膜性結腸炎。因此困難梭狀桿菌的預防及控制成為目前最重要的公共衛生議題。過去已知在歐美地區核醣型027為主要流行且具高毒性的菌株。然而,在其他世界地區卻觀察到有不同種的核醣型菌株的流行趨勢,在亞洲分佈的產毒株中核醣型017是主要的分型,比例約10%。許多研究發現核醣型017所引起困難梭狀桿菌感染的嚴重程度跟核醣型027很相似,然而,與核醣型027相比,核醣型017只具有tcdB一種毒素基因。在2015年至2016年的疾病管制署監測計畫中,我們實驗室從台灣五家醫院收集了1,112株困難梭狀桿菌,其中842株(75.8%)為產毒菌株,270株(24.2%)為非產毒菌株,其中核醣型017在產毒菌株中所佔的比例大約是9.97%。然而,目前尚不清楚RT017菌株為何會引起嚴重的疾病症狀,本研究,我們利用小鼠活體試驗,評估了RT017菌株的毒力,發現RT017菌株比CD630(RT012)菌株導致更嚴重的疾病症狀,與英國流行菌株R20291(RT027)相仿。通過體外的實驗發現,RT017之tcdB表達和其毒素葡糖基轉移酶活性均不如R20291高。與R20291相比,RT017菌株生物膜的形成與孢子形成率與R20291相似,而RT017的細菌聚集能力更強。此外,已知困難梭狀桿菌可產生自誘導物-2(AI-2),我們以哈氏弧菌MM32測量AI-2誘導生物發光的結果評估AI-2的表現量,發現RT017菌液中的AI-2表現量與R20291相似。將之誘導低毒力且低AI-2表現量之菌株(CD630),可誘導孢子形成能力增加。最後,以秀麗隱桿線蟲為模型生物,檢測菌液的毒性,發現RT017的菌液感染線蟲可降低其存活率,而加熱處理後的菌液則無法回復線蟲的存活率。綜合以上,我們發現RT017具高致病毒力、孢子形成能力及高表達量的AI-2,顯示可能與集中程度有關。
英文摘要 Clostridium. difficile causes nosocomial infection worldwide, especially in the patients with long-term usage of broad spectrum antibiotics. Clinical symptoms of C. difficile infections may present as diarrhea and pseudomembranous colitis (PMN). Therefore, controlling of C. difficile infection (CDI) is the most important public-health issues. In the United States and Europe, RT027 was known to be the epidemic and hypertoxigenic clone. However, the different epidemiologic trends in ribotype strain were observed in other continents. In Asia, RT017 is the predominant typeable ribotype in toxigenic strains, the prevalence rate is around 10% in Asia. Many studies demonstrated that the severity of CDI caused by RT 017 is similar to that caused by RT027. Compared to RT027, RT017 encodes only one toxin gene, tcdB. In a CDC surveillance program, 1,112 C. difficile isolates were collected from five hospitals from 2015 to 2016 in Taiwan. In this study, 842 (75.8%) strains were toxin-producing strains and 270 (24.2%) were non-toxigenic strains, where the proportion of RT017 in toxigenic strains was approximately 9.97%. However, it is unclear whether the RT017 strains cause severe diseases. Here, we evaluated the virulence of RT017 strain in vivo and found RT017 strain induced more severe disease symptoms than CD630 (RT012) did, but as well as a clinical UK epidemic C. difficile strain R20291 (RT027) did. By in vitro testing, both tcdB expression and toxin glucosyltransferase activity were not as high as R20291. Compared to R20291, biofilm formation in RT017 strains was similar to that in R20291, the aggregation ability in RT017 was stronger, spore formation rate of RT017 was similar to R20291. In addition, C. difficile produces small molecule, autoinducer-2 (AI-2), which can influence gene expression such as virulence, luminescence, and biofilm formation across different species. The levels of AI-2 that induces bioluminescence in Vibrio harveyi MM32 were measured. The AI-2 levels in RT017 spent medium is similar to that in R20291. Using spent medium of a less virulent strain (CD630), the spore formation was increased. Finally, used C. elegans as a model to examine the toxicity of spent medium, the survival rate was decreased when treating worms with spent medium of RT017 which cannot be reversed by heating the spent medium. Taken together, RT017 has higher virulence in vivo, ability in formation of spore, and higher AI-2 production, which might contribute to the disease progression.
論文目次 中文摘要 I
致謝 Ⅲ

1.1 Clostridium. difficile infection1
1.2 Virulence factors of CDI 2
1.3 Clinical diagnosis and treatment for Clostridium difficile infection 5
1.4 The epidemiology of C. difficile infection worldwide 6
1.5 PCR ribotype 017 (RT017) strain 7
1.6 The epidemiology of CDI in East Asia 9
1.7 The rationale in this study 10

2.1 Bacteria Strains 11
2.1.1 Clinical C. difficile isolates 11
2.1.2 Reference strains of C. difficile 11
2.2 CDI animal model 11
2.2.1 NF-κB-RE-luc transgenic (FVB) mice 11
2.2.2 In vivo imaging 12
2.3 TcdB mRNA level 12
2.3.1 Purified RNA 12
2.3.2 Reverse transcriptase PCR 14
2.3.3 RT-qPCR analysis 14
2.4 Toxin B activity 15
2.4.1 Cell line 15
2.4.2 Sample preparation and examine 15
2.4.3 Glucosyltransferase activity by western blot 15
2.5 Model animal toxicity test in C. elegans 17
2.5.1 Sample preparation 17
2.5.2 C. elegans preparation 17
2.5.3 Toxicity of C. elegans 18
2.6 Biofilm formation analysis 19
2.7 Aggregation ability 19
2.8 Spore formation 20
2.9 Autoinducer-2 (AI-2) expression 20
2.9.1 Sample collecting 20
2.9.2 Quorum sensing 21
2.10 Autoinducer-2 biological function 21
2.10.1 Autoinducer 2 (AI-2) effect on biofilm formation of low toxigenic CD630 strain 21

3.1 The epidemiology of C. difficile RT017 in Taiwan 23
3.2 RT017 strain induces NF-κB inflammatory responses as high as hypertoxigenic R20291 strain does 24
3.3 Toxin B levels in RT017 is not as high as that in hypertoxigenic R20291 strain 24
3.4 Biofilm-forming ability of RT017 is similar to hypertoxigenic R20291 strain and aggregation ability of RT017 is higher than hypertoxigenic R20291 strain 25
3.5 Spore formation rate of RT017 was as high as the hypertoxigenic R20291 strain 25
3.6 The AI-2 level in spent medium of RT017 is as high as that of other well-known hypertoxigenic strains 26
3.7 The AI-2 higher producer has the potential in induce more biofilm formation and spore formation but not tcdB expression 26
3.8 Spent medium of RT017 has the ability to inhibit Caenorhabditis elegans survival 27
參考文獻 1. Hall, I.C. and E. O'Toole, Intestinal flora in new-born infants: With a description of a new pathogenic anaerobe, bacillus difficilis. American Journal of Diseases of Children, 1935. 49(2): p. 390-402.
2. Balsells, E., et al., Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations. Journal of Global Health, 2016. 6(2): p. 020410.
3. Owens, J.R.C., et al., Antimicrobial-Associated Risk Factors for Clostridium difficile Infection. Clinical Infectious Diseases, 2008. 46(Supplement_1): p. S19-S31.
4. Kim, J., et al., Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics, 2008. 122(6): p. 1266-70.
5. Bien, J., V. Palagani, and P. Bozko, The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therapeutic Advances in Gastroenterology, 2013. 6(1): p. 53-68.
6. Hurley, B.W. and C.C. Nguyen, The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Archives of Internal Medicine, 2002. 162(19): p. 2177-2184.
7. Lima, A.A., et al., Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infection and Immunity, 1988. 56(3): p. 582-588.
8. Louie, T.J., Treatment of First Recurrences of Clostridium difficile-Associated Disease: Waiting for New Treatment Options. Clinical Infectious Diseases, 2006. 42(6): p. 765-767.
9. Thelestam, M. and E. Chaves-Olarte, Cytotoxic Effects of the Clostridium difficile Toxins, in Clostridium difficile, K. Aktories and T.D. Wilkins, Editors. 2000, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 85-96.
10. Riegler, M., et al., Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. Journal of Clinical Investigation, 1995. 95(5): p. 2004-2011.
11. Aktories, K., C. Schwan, and T. Jank, Clostridium difficile Toxin Biology. Annual Review of Microbiology, 2017. 71(1): p. 281-307.
12. Davies, Abigail H., et al., Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochemical Journal, 2011. 436(3): p. 517-526.
13. Just, I. and R. Gerhard, Large clostridial cytotoxins, in Reviews of Physiology, Biochemistry and Pharmacology. 2005, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 23-47.
14. Voth, D.E. and J.D. Ballard, Clostridium difficile Toxins: Mechanism of Action and Role in Disease. Clinical Microbiology Reviews, 2005. 18(2): p. 247-263.
15. Rupnik, M. and S. Janezic, An Update on Clostridium difficile Toxinotyping. Journal of Clinical Microbiology, 2016. 54(1): p. 13-18.
16. Shuttleworth, R., M. Taylor, and D.M. Jones, Antimicrobial susceptibilities of Clostridium difficile. Journal of Clinical Pathology, 1980. 33(10): p. 1002-1005.
17. Natarajan, M., et al., A Clinical and Epidemiological Review of Non-toxigenic Clostridium difficile. Anaerobe, 2013. 22: p. 1-5.
18. Carter, G.P., et al., Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. MBio, 2015. 6(3): p. e00551.
19. Schwan, C., et al., Clostridium difficile toxin CDT hijacks microtubule organization and reroutes vesicle traffic to increase pathogen adherence. Proceedings of the National Academy of Sciences of the United States of America, 2014. 111(6): p. 2313-2318.
20. Paredes-Sabja, D., A. Shen, and J.A. Sorg, Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends in Microbiology, 2014. 22(7): p. 406-416.
21. Colledge, V.L., et al., Structure and Organisation of SinR, the Master Regulator of Biofilm Formation in Bacillus subtilis. Journal of Molecular Biology, 2011. 411(3-26): p. 597-613.
22. Costerton, J.W., P.S. Stewart, and E.P. Greenberg, Bacterial Biofilms: A Common Cause of Persistent Infections. Science, 1999. 284(5418): p. 1318-1322.
23. Dawson, L.F., et al., Characterisation of Clostridium difficile Biofilm Formation, a Role for Spo0A. PLoS ONE, 2012. 7(12): p. e50527.
24. Dapa, T. and M. Unnikrishnan, Biofilm formation by Clostridium difficile. Gut Microbes, 2013. 4(5): p. 397-402.
25. Lee, A.S.Y. and K.P. Song, LuxS/autoinducer-2 quorum sensing molecule regulates transcriptional virulence gene expression in Clostridium difficile. Biochemical and Biophysical Research Communications, 2005. 335(3): p. 659-666.
26. Sperandio, V., et al., Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli. Proceedings of the National Academy of Sciences, 1999. 96(26): p. 15196-15201.
27. Bassler, B.L., How bacteria talk to each other: regulation of gene expression by quorum sensing. Current Opinion in Microbiology, 1999. 2(6): p. 582-587.
28. Carter, G.P., et al., Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. Journal of Medical Microbiology, 2005. 54(2): p. 119-127.
29. Waters, C.M. and B.L. Bassler, The Vibrio harveyi quorum-sensing system uses shared regulatory components to discriminate between multiple autoinducers. Genes & Development, 2006. 20(19): p. 2754-2767.
30. Hunt, P.R., The C. elegans model in toxicity testing. Journal of Applied Toxicology, 2017. 37(1): p. 50-59.
31. Burnham, C.-A.D. and K.C. Carroll, Diagnosis of Clostridium difficile Infection: an Ongoing Conundrum for Clinicians and for Clinical Laboratories. Clinical Microbiology Reviews, 2013. 26(3): p. 604-630.
32. Lo Vecchio, A. and G.M. Zacur, Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol, (1531-7056 (Electronic)).
33. Wang, P., et al., Identification of Clostridium difficile ribotype 027 for the first time in Mainland China. Infect Control Hosp Epidemiol, 2014. 35(1): p. 95-8.
34. Hubert, B., et al., A Portrait of the Geographic Dissemination of the Clostridium difficile North American Pulsed-Field Type 1 Strain and the Epidemiology of C. difficile-Associated Disease in Québec. Clinical Infectious Diseases, 2007. 44(2): p. 238-244.
35. Drudy, D., et al., gyrA Mutations in Fluoroquinolone-resistant Clostridium difficile PCR-027. Emerging Infectious Diseases, 2007. 13(3): p. 504-505.
36. Goorhuis, A., et al., Clostridium difficile PCR Ribotype 078: an Emerging Strain in Humans and in Pigs? Journal of Clinical Microbiology, 2008. 46(3): p. 1157-1158.
37. Putsathit, P., et al., Prevalence and molecular epidemiology of Clostridium difficile infection in Thailand. New Microbes and New Infections, 2017. 15: p. 27-32.
38. Komatsu, M., et al., High Frequency of Antibiotic-Associated Diarrhea due to Toxin A-Negative, Toxin B-Positive Clostridium difficile in a Hospital in Japan and Risk Factors for Infection. European Journal of Clinical Microbiology and Infectious Diseases, 2003. 22(9): p. 525-529.
39. Tang, C., et al., The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis. Scientific Reports, 2016. 6: p. 37865.
40. Joana, I., et al., Imipenem Resistance in Clostridium difficile Ribotype 017, Portugal. Emerging Infectious Disease journal, 2018. 24(4): p. 741.
41. Kim, J., et al., Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clinical Microbiology and Infection, 2013. 19(6): p. 521-527.
42. Jin, D., et al., Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China. Journal of Clinical Microbiology, 2017. 55(3): p. 801-810.
43. Liu, X.-s., et al., Molecular Characterization of Clostridium difficile Isolates in China From 2010 to 2015. Frontiers in Microbiology, 2018. 9: p. 845.
44. Cairns, M.D., et al., Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages. Journal of Clinical Microbiology, 2017. 55(3): p. 865-876.
45. Darkoh, C., et al., Toxin Synthesis by Clostridium difficile Is Regulated through Quorum Signaling. mBio, 2015. 6(2): p. e02569-14.
46. Martin, M.J., et al., The agr Locus Regulates Virulence and Colonization Genes in Clostridium difficile 027. Journal of Bacteriology, 2013. 195(16): p. 3672-3681.
47. Drudy, D., et al., Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile. Infection Control & Hospital Epidemiology, 2015. 28(8): p. 932-940.
48. Freeman, J., et al., Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clinical Microbiology and Infection, 2015. 21(3): p. 248.e9-248.e16.
49. Borren, N.Z., et al., The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLOS ONE, 2017. 12(5): p. e0176797.
50. Hung, Y.-P., et al., Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan. PLOS ONE, 2016. 11(11): p. e0166159.
51. Cury, J.A. and H. Koo, Extraction and purification of total RNA from Sreptococcus mutans biofilms. Analytical Biochemistry, 2007. 365(2): p. 208-214.
52. Fogh, J. and G. Trempe, New Human Tumor Cell Lines, in Human Tumor Cells in Vitro, J. Fogh, Editor. 1975, Springer US: Boston, MA. p. 115-159.
53. Li, S., et al., Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis. Infection and Immunity, 2015. 83(2): p. 502-513.
54. Aslim, B., Y. Onal D Fau - Beyatli, and Y. Beyatli, Factors influencing autoaggregation and aggregation of Lactobacillus delbrueckii subsp. bulgaricus isolated from handmade yogurt. (0362-028X (Print)).
55. Purcell, E.B., et al., Cyclic Diguanylate Inversely Regulates Motility and Aggregation in Clostridium difficile. Journal of Bacteriology, 2012. 194(13): p. 3307-3316.
56. Burns, D.A. and N.P. Minton, Sporulation studies in Clostridium difficile. Journal of Microbiological Methods, 2011. 87(2): p. 133-138.
57. Darkoh, C., et al., Toxin Synthesis by Clostridium difficile Is Regulated through Quorum Signaling. mBio, 2015. 6(2).
58. Best, E.L., et al., The Potential for Airborne Dispersal of Clostridium difficile from Symptomatic Patients. Clinical Infectious Diseases, 2010. 50(11): p. 1450-1457.
59. Cairns, M.D., et al., Genomic Epidemiology of a Protracted Hospital Outbreak Caused by a Toxin A-Negative Clostridium difficile Sublineage PCR Ribotype 017 Strain in London, England. Journal of Clinical Microbiology, 2015. 53(10): p. 3141-3147.
60. Kullin, B., et al., Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa. European Journal of Clinical Microbiology & Infectious Diseases, 2016. 35(10): p. 1709-1718.
61. Soavelomandroso, A.P., et al., Biofilm Structures in a Mono-Associated Mouse Model of Clostridium difficile Infection. Frontiers in Microbiology, 2017. 8(2086).
62. Ðapa, T., et al., Multiple Factors Modulate Biofilm Formation by the Anaerobic Pathogen Clostridium difficile. Journal of Bacteriology, 2013. 195(3): p. 545-555.
63. Rollins, S.M. and R. Schuch, Crowd control: Bacillus anthracis and quorum sensing. Virulence, 2010. 1(2): p. 57-9.
64. Subramanian, S., et al., Autoinducer-2 analogs and electric fields - an antibiotic-free bacterial biofilm combination treatment. Biomedical Microdevices, 2016. 18(5): p. 95.
  • 同意授權校內瀏覽/列印電子全文服務,於2020-08-28起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2020-08-28起公開。

  • 如您有疑問,請聯絡圖書館